Sarepta Therapeutics, Inc. (SRPT) Analysts See $-0.32 EPS

April 16, 2018 - By Michael Collier

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) LogoInvestors sentiment decreased to 1.22 in Q4 2017. Its down 1.66, from 2.88 in 2017Q3. It fall, as 27 investors sold Sarepta Therapeutics, Inc. shares while 67 reduced holdings. 45 funds opened positions while 70 raised stakes. 52.88 million shares or 2.28% more from 51.70 million shares in 2017Q3 were reported.
Gilder Gagnon Howe Co Ltd Co reported 0.65% stake. Strs Ohio reported 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Moreover, Principal Financial Grp Incorporated has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 19,416 shares. 32,891 were reported by Stifel Corporation. Moreover, Natixis has 0.01% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 13,560 shares. Raymond James Associate stated it has 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). First Allied Advisory Services holds 0.02% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 9,041 shares. New York-based Metropolitan Life Insurance New York has invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). North Star Investment Management invested in 0% or 735 shares. Riggs Asset Managment holds 0% or 35 shares. Wells Fargo & Company Mn, California-based fund reported 287,246 shares. 16,507 were reported by Janney Montgomery Scott Ltd Company. 2,300 were accumulated by Glenmede Trust Communication Na. United Financial Advisers Ltd Liability Corporation stated it has 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Raymond James Svcs Advsr invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Analysts expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report $-0.32 EPS on April, 26.They anticipate $0.41 EPS change or 56.16 % from last quarter’s $-0.73 EPS. After having $-0.37 EPS previously, Sarepta Therapeutics, Inc.’s analysts see -13.51 % EPS growth. The stock decreased 1.96% or $1.58 during the last trading session, reaching $79.22. About 493,369 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 149.90% since April 16, 2017 and is uptrending. It has outperformed by 138.35% the S&P500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 15 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 13 have Buy rating, 0 Sell and 2 Hold. Therefore 87% are positive. Sarepta Therapeutics had 25 analyst reports since October 17, 2017 according to SRatingsIntel. As per Tuesday, March 6, the company rating was maintained by Morgan Stanley. Piper Jaffray maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Thursday, October 26 with “Buy” rating. H.C. Wainwright maintained the shares of SRPT in report on Monday, March 12 with “Buy” rating. The firm earned “Buy” rating on Wednesday, March 7 by SunTrust. The stock has “Buy” rating by Piper Jaffray on Friday, March 2. J.P. Morgan maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Wednesday, February 21 with “Buy” rating. The rating was maintained by Needham on Thursday, October 26 with “Buy”. On Tuesday, October 17 the stock rating was maintained by Robert W. Baird with “Buy”. Barclays Capital maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Thursday, October 26 with “Equal-Weight” rating. The company was maintained on Wednesday, March 14 by JP Morgan.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $5.15 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.